Ciprofloxacin

Abstract

Ciprofloxacin is a new fluorinated quinolone antibiotic with high activity against a wide spectrum of gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas aeruginosa. Clinical trials using the oral preparation of ciprofloxacin have demonstrated its effectiveness in a wide variety of infections. In addition, extensive clinical trials with the intravenous preparation are underway. In vitro and in vivo studies with ciprofloxacin have reported the incidence of resistant organisms to be very low. In addition, the incidence of ciprofloxacin-related side effects throughout its clinical trials has been minimal. Most reports of side effects have been related to the gastrointestinal tract, such as nausea or vomiting. The incidence of adverse experiences in worldwide clinical trials has been reported to be approximately 6.4 percent.